Accelerated cancer registration from the National Disease Registration Service to support the NHS-Galleri trial

The National Disease Registration Service successfully implemented accelerated cancer registration products to deliver high-quality, timely data with high concordance to support the rapid analysis of the NHS-Galleri multi-cancer early detection trial.

The Gist

Imagine the National Health Service (NHS) in England is like a massive, busy library. Every time someone is diagnosed with cancer, a new book is written about their case. Usually, this library takes a long time—about 18 to 20 months—to organize, proofread, and put these books on the shelves so researchers can read them.

But for a giant experiment called the NHS-Galleri trial, the researchers needed to read these books much faster. They were testing a new blood test that could find cancer early. To know if the test worked, they needed to see the results quickly, not wait nearly two years.

Here is how the National Disease Registration Service (NDRS), the "librarians" of this system, solved the problem.

The Problem: The "Slow Mail" vs. The "Express Lane"

Normally, getting cancer data is like sending a letter via standard post. It's reliable, but it takes a while because the librarians have to check every single detail against multiple sources to make sure it's perfect before they let anyone see it.

For the Galleri trial, waiting that long would mean the trial results would be outdated by the time they arrived. The researchers needed an Express Lane.

The Solution: Two "Express" Packages

The librarians created two special, fast-track services for the trial participants:

1. The "Expedited Core" (The 6-Month Snapshot):
   Think of this as a fast-food burger. It's not the full gourmet meal with all the sides yet, but it has the main ingredients you need: What is the cancer? Where is it? How big is it (Stage)?

   • Goal: Get this data out just 6 months after diagnosis.
   • Result: They managed to get 98% of the "burgers" ready by this time.

2. The "Expedited Comprehensive" (The 11-Month Snapshot):
   This is the full gourmet meal. It includes everything in the Core package, plus the "sides and dessert"—which is the treatment history (what happened in the hospital over the next 6 months).

   • Goal: Get this data out 11 months after diagnosis.
   • Result: By this time, 100% of the registrations were ready.

How They Did It: The "Concierge" Team

You might wonder, "How can you speed up a process that usually takes so long without making mistakes?"

The librarians didn't just work faster; they worked smarter with extra help:

• The Dedicated Concierge: They hired a special team whose only job was to chase the hospitals for missing information. Instead of waiting for hospitals to send data on their own schedule, this team called them, nudged them, and helped them fill in the blanks immediately.
• The Automated Conveyor Belt: They built a special machine (software) that automatically sorted the trial participants' files and put them at the front of the line, so they were processed before the regular, non-trial files.
• The "Blind" Review: To keep things fair, the librarians didn't know which patients were getting the new blood test and which were in the control group. They just processed the data based on the facts, ensuring the results weren't biased.

Did It Work? (The Taste Test)

The big question was: Is the "fast food" as good as the "slow-cooked meal"?

The researchers compared the data at 6 months, 11 months, and 19 months (the normal time).

• The Verdict: The data was 96% to 99% identical.
• The Analogy: Imagine you take a photo of a building at 6 months, and then take another photo of the same building at 19 months. If you look at the main structure (the cancer stage and type), the photos look almost exactly the same. The only tiny differences were minor details that got filled in later, like the color of the front door.

Why This Matters

This was a world-first achievement. Usually, getting high-quality cancer data with stage information takes nearly two years. The NDRS proved that with enough resources and a dedicated team, you can get high-quality, reliable data in just 6 months.

The Bottom Line:
This new "Express Lane" allowed the NHS-Galleri trial to report its findings about a year earlier than usual. This means doctors and patients can learn if this new blood test works much sooner, potentially saving lives by catching cancer earlier, without sacrificing the accuracy of the science.

It's like proving you can bake a perfect cake in half the time, as long as you have the right oven and a dedicated baker watching the timer!

Technical Summary

1. Problem Statement

The National Disease Registration Service (NDRS) in England maintains the National Cancer Registration Dataset (NCRD), a high-quality, population-based dataset used for health planning and research. However, routine cancer registration data typically becomes available only 18–20 months after diagnosis.

This latency posed a critical bottleneck for the NHS-Galleri trial (NCT05611632), a large randomized controlled trial assessing a multi-cancer early detection (MCED) blood test. The trial's primary objective is to measure the reduction in late-stage (Stage III/IV) cancer incidence. To evaluate the clinical utility of the MCED test effectively and report findings in a timely manner, the trial required detailed, high-quality cancer diagnosis and staging data substantially earlier than the standard 18–20 month window.

2. Methodology

To address the latency issue, NDRS developed a novel, accelerated registration framework specifically for NHS-Galleri trial participants. The methodology involved four key components:

• Two-Tiered Accelerated Products:

  • Expedited Core: Delivered 6 months post-diagnosis. This dataset included the diagnosis date, topography, morphology, behavior, basis of diagnosis, and crucially, cancer stage.
  • Expedited Comprehensive: Delivered 11 months post-diagnosis. This included all "Core" data plus at least 6 months of follow-up clinical pathway data (primarily treatment), ensuring records were up-to-date regarding stage changes or treatment cessation.

• Data Linkage and Processing:

  • The unblinded trial team uploaded participant cohort data monthly to a secure NDRS portal.
  • Automated processes within the ENCORE (English National Cancer Online Registration Environment) system linked incoming NHS data to trial participants using NHS numbers.
  • Cancer Registration Officers (CROs) processed data on a priority basis. They created "Provisional" registrations immediately upon receiving initial data, then refined them into "Expedited Core" at the 6-month mark and "Expedited Comprehensive" at the 11-month mark.

• Enhanced Data Liaison:

  • NDRS established a dedicated data liaison team (funded by GRAIL Bio UK) to proactively contact NHS Trusts.
  • This team monitored missing or inconsistent data (specifically stage and treatment) and worked directly with providers to resolve queries, ensuring high completeness within the accelerated timeline.

• Quality Assurance (QA):

  • Rigorous QA checks were embedded at the individual record level.
  • Monthly reports were generated for the trial team to monitor data quality and completeness.
  • Strict confidentiality protocols were maintained, with staff largely blinded to intervention/control arm assignments.

3. Key Contributions

• Operational Innovation: The paper describes the first successful implementation of high-quality, stage-complete cancer registration data at 6 months post-diagnosis, a significant reduction from the global median of ~20 months.
• Scalable Framework: The study demonstrates that routine national registry infrastructure can be adapted with dedicated resources and automated processes to support large-scale clinical trials without compromising data integrity.
• Validation of Accelerated Data: The study provides empirical evidence that accelerated data maintains high concordance with routine long-term data, validating its use for primary trial endpoints.

4. Results

The study analyzed the December 2023 data snapshot for trial participants diagnosed between October 2021 and November 2023.

• Timeliness:

  • <6 months: 2.8% of registrations were "Provisional."
  • 6–10 months: 28.5% achieved "Expedited Core" status.
  • >11 months: 68.7% achieved "Expedited Comprehensive" status.
  • By the 19-month mark, 99.97% of registrations were "Expedited Comprehensive."

• Data Concordance (Quality):

  • Comparisons between snapshots at 6, 11, and 19 months showed high agreement.
  • Fact of Malignant Cancer: 96.7% concordance between 6 and 19 months.
  • Stage III/IV Diagnosis: 95.6% concordance between 6 and 19 months.
  • Stage Concordance: Was highest (≥99.7%) for records that remained "Expedited Comprehensive" across snapshots. Lower concordance (57.1%) was observed when transitioning from "Provisional" to "Expedited Comprehensive," attributed to the initial lack of staging data in provisional records.

• Reasons for Discordance:

  • The majority of discrepancies were due to registrations not yet existing in earlier snapshots (e.g., a diagnosis date change or a record not yet created).
  • Only a small percentage (<3.1%) of records changed status due to data correction (e.g., behavior code changes).

5. Significance

• Accelerated Trial Reporting: This approach enables the NHS-Galleri trial to report findings approximately 13 months earlier than would be possible using routine data flows.
• Global Benchmark: The production of high-quality, stage-complete cancer registration data at 6 months post-diagnosis is described as a world-first.
• Resource Efficiency: While the process required additional upfront and ongoing resources (dedicated liaison, technical development), it offers a superior alternative to burdensome, expensive, and fragmented data extraction directly from clinical trial sites.
• Public Health Impact: By facilitating faster evaluation of MCED screening, this methodology supports the potential rapid deployment of life-saving early detection technologies, ultimately aiming to reduce the burden of late-stage cancer diagnoses.

Conclusion: The NDRS successfully adapted its routine data flows to deliver timely, high-fidelity cancer registration data for a major clinical trial. The high concordance between accelerated and routine data confirms that such acceleration is feasible without sacrificing the quality required for rigorous epidemiological analysis.